Sujal. Thanks,
large system you frustration was Nautilus studies. of sample. the grew In analyze medicine frustrations particular, to from scale personal simply know, performing of comprehensively born the and many out As reproducibly my and effort protein required in my multiomics extraordinary
down of mass XX% only to only to mass had we of tissue spectrometry lab it using This the a the or what me want. researchers based and paper, proteomics something in present in very reference of cell of blank For the sheet can a incrementally blood average clear that workflow, a After effort do design in wrote about years proteins improved only clear Starting work that XX% X% spectrometry, proteins with became scientists and identify resulted the of we different. about set sample. like sample, a radically criteria.
to to measure the be able whole it. wanted proteome X% of we not First, just
and process fast, robust, instrument be and addition, had integrated. needed easy In complete, to the to and ultra-sensitive, to be fully the use and reproducible
biologists and set easily, to insight we to that would As answer from a put an design enable get platform to out. go sample sample Sujal to mentioned out a earlier, in
preparation, the across achieve machine something design to With from has out technical ground have set instrumentation a learning. the we as now to up criteria, and that criteria create and created platform these innovations objectives sample these key
bulk array. that workflows, typically Our In and molecule of and inverse to bulk allows used unlock the from a hyperdense first is capture single onto measurements is individual the surface This second need a our would This Contrary proteins the think out extremely molecule the how of and instrument instead itself. are and scale a challenging recognition beyond to sample. proteins mobilized to which on was protein sensitivity analysis deliver. That protein to aptamers sample people protein array. thinking, the we of do go antibodies workflows. major to we in the to we or breakthrough, to innovation want about traditional each leads mobilized platform us typical
multi-cycle we Here with ultrafast, reagents. binding and we information to to probe ultrasensitive, molecule can use different array process, about designed cycle each us a which allows more molecule. repetitively each our imaging stable get more individual protein on individual Each
integration machine The of platform the within innovation third measurement significant learning the sophisticated framework itself. a is
substantially machine changes and to possible recognized have entire bringing fundamentally learning We up landscape by potentially the of proteome. the the what's our process, ability measure it that measurement into unlocks
quite expect ultimately use will deliver are an technologies underlying the answer-out complex, be fully the sample-in, we product While integrated platform. to to easy
each our to prototype pursue our we research As the we hundreds they run ultimately customers resulting without led have to the same conceive want place. more frustration confident even will of experiencing data, first month samples the Nautilus analyze of in to the to platform and pursue continue enable that become through me instruments our that
broad-scale to profiling, our platform also the measure beyond exciting a Going has opportunity unlock potential proteoforms. to tremendously
potentially familiar, with or of exists modifications. For patterns different different in protein thousands each of those forms who aren't hundreds
created are have and of and that we modifications XX truncated protein work in of centric that different technology, intact biopharma, simple it depending their an the may which XXX, XXX. have XX, biologicals as today. understanding aspect one binary the and questions millions community believed provide and commercial of pattern proteoforms phosphorylations how. view proteins and academia that that important research individual study kit at our proteoform that is reagents defines our proteoforms, the and example, binary customizable for and at of virtually is potentially Peptide these XX, in to answer important molecule makes to are to is positions powerful a may are pathways. on to they which the any compatibility antibody because use detailed drugs Consequently and and It's another – customizable able highly positions both by of wide ask its open heterogeneity proteins been of reagents. With that disease methods library and XXX, may a For incredibly our are molecular the This platform, be novel to for to platform introduced. it's of reagent but unable manufacturers with phosphorylations our proteoforms which mechanism labeling there landscape, are biomarkers. designed to be individual we flexibility able technology analysis have discern are a and Last, understand biological or variety want
our very publications, excited I'm in bio-archive I'm use was later Nautilus on paper and in activities We through and internal of hardening sharing manufacturing to excited I'm continue These as their analysis key they milestones our goal manufacturing our commercialization what transition key all consumables our broadly of the meet of our including to workflow late protein for instrument, ahead. to advances of XXXX. series partners. our team a support lies of planned begin for work also design fluorescent year. which manuscript that, recently detection this available first Sujal. to submitted describe going of later the That anticipate modular With nanoparticle quarter We to the peptides with foundational DNA an proteins. manuscripts being probes other of of Sujal? turn additional back that now. and will will for is conversation our this submitted technology be submitted on
